Health-related quality of life in children and adolescents born very preterm and its correlates: a cross-sectional study.


Journal

BMJ paediatrics open
ISSN: 2399-9772
Titre abrégé: BMJ Paediatr Open
Pays: England
ID NLM: 101715309

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 08 07 2024
accepted: 02 10 2024
medline: 11 10 2024
pubmed: 11 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

We aimed to assess health-related quality of life (HRQOL) in a cohort of very preterm born children and adolescents (aged 5-16), and to compare it with their fullterm born siblings and the general population. We also explored correlates of HRQOL among the very preterm born. Cross-sectional survey. Children born <32 weeks gestation (N=442) as well as their fullterm born siblings (N=145). Primary outcome was KINDL total score (0 worst to 100 best), a validated multidimensional measure of HRQOL in children and adolescents. Linear mixed models accounted for family unit. Secondary analysis compared very preterm born children to another cohort of healthy children from the same time period. A classification tree analysis explored potential correlates of HRQOL. On average, preterm children, both <28 and 28-31 weeks gestational age, had similar KINDL total score to fullterm sibling controls (-2.3, 95% CI -3.6 to -0.6), and to population controls (+1.4, 95% CI 0.2 to 2.5). Chronic non-respiratory health conditions (such as attention deficit hyperactivity disorder or heart conditions, but not including cerebral palsy), age and respiratory symptoms affecting daily life were key correlates of HRQOL among very preterm born children. Very preterm birth in children and adolescents was not associated with a relevant reduction in HRQOL compared with their fullterm born peers. However, lower HRQOL was explained by other factors, such as older age, and the presence of chronic non-respiratory health conditions, but also by possibly modifiable current respiratory symptoms. The influence of respiratory symptom amelioration and its potential influence on HRQOL needs to be investigated further. NCT04448717.

Identifiants

pubmed: 39389623
pii: 10.1136/bmjpo-2024-002885
doi: 10.1136/bmjpo-2024-002885
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04448717']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: MA receives a salary as network coordinator for the Swiss Neonatal Network. The other authors declare no conflicts of interest related to this work.

Auteurs

Sarah R Haile (SR)

Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.

Gabriela P Peralta (GP)

Pompeu Fabra University, Barcelona, Spain.
CIBERESP, Madrid, Spain.

Mark Adams (M)

Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.
Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.

Ajay N Bharadwaj (AN)

Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.
Department of Health Sciences and Technology, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.

Dirk Bassler (D)

Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.

Alexander Moeller (A)

Division of Respiratory Medicine, University Children's Hospital Zurich, Zurich, Switzerland.

Giancarlo Natalucci (G)

Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.

Thomas Radtke (T)

Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.

Susi Kriemler (S)

Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland susi.kriemlerwiget@uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH